BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37097530)

  • 21. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
    Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
    Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics.
    Hung YP; Fletcher CDM; Hornick JL
    Histopathology; 2018 Oct; 73(4):634-644. PubMed ID: 29863809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intestinal infantile fibrosarcoma with translocation of NTRK. A case report and review of the literature.
    Soler PM; Duque MSR; Juan GM; Terán AKC; Calvo ART; Cobo MLC
    Rev Esp Patol; 2023; 56(2):76-81. PubMed ID: 37061245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
    Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
    Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience.
    Orbach D; Brennan B; De Paoli A; Gallego S; Mudry P; Francotte N; van Noesel M; Kelsey A; Alaggio R; Ranchère D; De Salvo GL; Casanova M; Bergeron C; Merks JH; Jenney M; Stevens MC; Bisogno G; Ferrari A
    Eur J Cancer; 2016 Apr; 57():1-9. PubMed ID: 26849118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
    Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
    Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies.
    Orbach D; Sparber-Sauer M; Laetsch TW; Minard-Colin V; Bielack SS; Casanova M; Corradini N; Koscielniak E; Scheer M; Hettmer S; Bisogno G; Hawkins DS; Ferrari A
    Eur J Cancer; 2020 Sep; 137():183-192. PubMed ID: 32784118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recurrent and metastatic infantile fibrosarcoma: a case report].
    Lagree M; Toutain F; Revillon Y; Gaussin G; Marie-Cardine A; Lemoine F; Vannier JP
    Arch Pediatr; 2011 Jan; 18(1):28-32. PubMed ID: 21084177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infantile NTRK-associated Mesenchymal Tumors.
    Davis JL; Lockwood CM; Albert CM; Tsuchiya K; Hawkins DS; Rudzinski ER
    Pediatr Dev Pathol; 2018; 21(1):68-78. PubMed ID: 28683589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second Report of
    Hughes CE; Correa H; Benedetti DJ; Smith B; Sumegi J; Bridge J
    Pediatr Dev Pathol; 2021; 24(6):554-558. PubMed ID: 34120511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Nagasubramanian R; Wei J; Gordon P; Rastatter JC; Cox MC; Pappo A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1468-70. PubMed ID: 27093299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
    Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
    Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases.
    Lapeña LM; Caldas MCS; Ramírez C; Basilio MS; Junco PT; Rodríguez-Laguna L; Martínez-González V; Marín-Manzano E; Perez-Martinez A; Lopez-Gutierrez JC
    European J Pediatr Surg Rep; 2022 Jan; 10(1):e76-e79. PubMed ID: 35761904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
    Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
    Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.
    Shulman DS; DuBois SG
    Paediatr Drugs; 2020 Apr; 22(2):189-197. PubMed ID: 31965543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging characterization of paediatric tumours with the neurotrophic tyrosine receptor kinase fusion transcript.
    Hermann AL; Lemelle L; Pierron G; Gauthier A; Nicolas N; Cardoen L; Moalla S; Petit P; Morel B; Ducou Le Pointe H; Hassani A; Fréneaux P; Guillemot D; Carton M; Corradini N; Rome A; Castex MP; Defachelles AS; Schleiermacher G; Berlanga P; Delattre O; Orbach D; Brisse HJ
    Br J Radiol; 2024 Mar; 97(1156):734-743. PubMed ID: 38327010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm.
    Wong DD; Vargas AC; Bonar F; Maclean F; Kattampallil J; Stewart C; Sulaiman B; Santos L; Gill AJ
    Pathology; 2020 Jun; 52(4):401-409. PubMed ID: 32278476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
    Boyarskikh UA; Savostyanova TA; Oscorbin IP; Filipenko ML
    Bull Exp Biol Med; 2023 May; 175(1):132-137. PubMed ID: 37338765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
    Church AJ; Calicchio ML; Nardi V; Skalova A; Pinto A; Dillon DA; Gomez-Fernandez CR; Manoj N; Haimes JD; Stahl JA; Dela Cruz FS; Tannenbaum-Dvir S; Glade-Bender JL; Kung AL; DuBois SG; Kozakewich HP; Janeway KA; Perez-Atayde AR; Harris MH
    Mod Pathol; 2018 Mar; 31(3):463-473. PubMed ID: 29099503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
    Rubin BP; Chen CJ; Morgan TW; Xiao S; Grier HE; Kozakewich HP; Perez-Atayde AR; Fletcher JA
    Am J Pathol; 1998 Nov; 153(5):1451-8. PubMed ID: 9811336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.